CAS No.: 2098191-53-6
eFT226 is a novel, potent and selective eIF4A inhibitor with anti-tumor activity in B-cell malignancies, promotes eIF4A binding to specific mRNA sequences and interferes with the assembly of the eIF4F initiation complex
Packing | Price | Stock | Quantity |
---|---|---|---|
100 mg | Get quote | ||
250 mg | Get quote | ||
1 g | Get quote |
E-mail: sales@hmobio.com
Tech Support: services@hmobio.com
eFT226 is a novel, potent and selective eIF4A inhibitor with anti-tumor activity in B-cell malignancies, promotes eIF4A binding to specific mRNA sequences and interferes with the assembly of the eIF4F initiation complex; selectively inhibits translation of mRNAs containing longer 5'-UTRs, an increased frequency of uORFs (upstream open reading frame), and polypurine and/or G-quadraplex recognition motifs; demonstrates potent inhibition of reporter constructs containing a polypurine motif in the 5'-UTR with IC50 of 2 nM, shows potent anti-proliferative activity (EC50) and an induction of apoptosis against a panel of B-cell lymphoma cell lines, dose-dependently decreases the oncogenic drivers c-MYC, CCND1/3, BCL2 or MCL-1; shows in vivo activity across hematological tumor models. Zotatifin shows robust antiviral effects, it effectively reduces viral infectivity by inhibiting SARS-CoV-2 NP protein biogenesis (IC90=37 nM). Zotatifin induces cell apoptosis.
M.Wt | 487.55 | |
Formula | C28H29N3O5 | |
CAS No. | 2098191-53-6 | |
Storage |
|
|
Chemical Name/SMILES | N#CC1=CC=C([C@@]2(O3)[C@@](C4=C3C=C(OC)N=C4OC)(O)[C@H](O)[C@H](CN(C)C)[C@H]2C5=CC=CC=C5)C=C1 |
086-18516630705
sales@hmobio.com
1/F, building 4, No. 358-368, Kefu Road, Jiading District, Shanghai, China